STAA logo

STAAR Surgical Company (STAA)

$25.56

Quotes are delayed by 15 minutes.

1D

1W

1M

3M

6M

YTD

1Y

2Y

5Y

ALL

Key data on STAA

Market cap

$1.28B

EPS

0.01

P/E ratio

361.1

Price to sales

3.2

Dividend yield

--

Beta

1.225659

Price on STAA

Previous close

$26.01

Today's open

$25.89

Day's range

$25.19 - $25.89

52 week range

$15.59 - $35.87

Profile about STAA

CEO

Stephen C. Farrell

Employees

957

Headquarters

Lake Forest, CA

Exchange

NASDAQ Global Market

Shares outstanding

50201819

Issue type

Common Stock

STAA industries and sectors

Healthcare

Medical Equipment & Supplies

News on STAA

What STAAR Surgical (STAA) Said on Its Q3 Earnings Call

STAAR Surgical NASDAQ: STAA reported lower third-quarter sales and profit on a reported basis, but said revenue rose 21% after excluding a prior-year deferred sales item in China. The implantable lens maker also said demand for higher-priced products in China exceeded its ability to supply them during the quarter.

news source

MarketBeat • Nov 5, 2026

news preview

STAAR Surgical Company (STAA) Q3 2026 Earnings Call Transcript

STAAR Surgical Company (STAA) Q3 2026 Earnings Call Transcript

news source

Seeking Alpha • Nov 5, 2026

news preview

STAAR Surgical Reports Third Quarter 2026 Results

LAKE FOREST, Calif.--(BUSINESS WIRE)--STAAR Surgical Company (“STAAR” or the “Company”) (NASDAQ: STAA), the global leader in phakic IOLs with the EVO™ family of Implantable Collamer® Lenses (EVO ICL™) for vision correction, today reported results for the third quarter ended October 2, 2026. The Company will host an earnings call and webcast today at 5:30 PM Eastern Time. Third Quarter and Year-to-Date 2026 Highlights Include: Net sales down 12% Y/Y; up 21% excluding a 33-percentage point ($25.9.

news source

Business Wire • Nov 4, 2026

news preview

Staar Surgical (STAA) Surpasses Q3 Earnings and Revenue Estimates

Staar Surgical (STAA) came out with quarterly earnings of $0.34 per share, beating the Zacks Consensus Estimate of $0.19 per share. This compares to earnings of $0.46 per share a year ago.

news source

Zacks Investment Research • Nov 5, 2026

news preview

STAAR Surgical Appoints Pascal Aeschlimann as Vice President of Asia Pacific

LAKE FOREST, Calif.--(BUSINESS WIRE)--STAAR Surgical Company (“STAAR” or the “Company”) (NASDAQ: STAA), the global leader in phakic IOLs with the EVO family of Implantable Collamer® Lenses (EVO ICL™) for vision correction, today announced the appointment of Pascal Aeschlimann as Vice President of Asia Pacific, effective November 2, 2026. Mr. Aeschlimann, who led STAAR's commercial expansion across Asia and the Middle East from 2002 to 2010, returns after more than a decade building and leading.

news source

Business Wire • Oct 29, 2026

news preview

Earnings Preview: Staar Surgical (STAA) Q3 Earnings Expected to Decline

Staar Surgical (STAA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

news source

Zacks Investment Research • Oct 28, 2026

news preview

STAAR Surgical to Participate in Upcoming Investor Conferences

LAKE FOREST, Calif.--(BUSINESS WIRE)--STAAR Surgical Company (NASDAQ: STAA), the global leader in phakic IOLs with the EVO™ family of Implantable Collamer® Lenses (EVO ICL™) for vision correction, today announced that Warren Foust, President and Chief Executive Officer, and Deborah Andrews, Executive Vice President and Chief Financial Officer, will participate in two investor conferences in November: Stifel 2026 Healthcare Conference Date: Tuesday, November 10, 2026 Location: New York, NY Fires.

news source

Business Wire • Oct 27, 2026

news preview

STAAR Surgical to Host Third Quarter 2026 Earnings Results Call and Webcast on November 4, 2026

LAKE FOREST, Calif.--(BUSINESS WIRE)--STAAR Surgical Company (NASDAQ: STAA), the global leader in phakic IOLs with the EVO family of Implantable Collamer® Lenses (EVO ICL™) for vision correction, today announced that it will release financial results and a letter to shareholders for the third quarter ended October 2, 2026, on Wednesday, November 4, 2026, after the market close. The Company will also host an earnings call and webcast at 5:30 p.m. ET that same day to discuss its financial results.

news source

Business Wire • Oct 21, 2026

news preview

SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Shareholders of an Investigation Concerning Possible Breaches of Fiduciary Duties by Certain Officers and Directors of STAAR Surgical Company (NASDAQ: STAA)

NEW YORK, Oct. 21, 2026 /PRNewswire/ -- Levi & Korsinsky announces that it has commenced an investigation of STAAR Surgical Company (NASDAQ: STAA) concerning possible breaches of fiduciary duties. If you are a current shareholder of STAA, you can request additional information here: https://zlk.com/cases/staar-surgical-company-class-action-lawsuit-staa-3 or contact Joseph E.

news source

PRNewsWire • Oct 21, 2026

news preview

STAAR Surgical Names Andrew Pilon as Vice President of Business Development

LAKE FOREST, Calif.--(BUSINESS WIRE)--STAAR Surgical Company (“STAAR” or the “Company”) (NASDAQ: STAA), the global leader in phakic IOLs with the EVO family of Implantable Collamer® Lenses (EVO ICL™) for vision correction, today announced the appointment of Andrew Pilon, O.D. as Vice President of Business Development. Dr. Pilon will report to STAAR President and Chief Executive Officer Warren Foust and will work closely with the Company's senior leadership team to capitalize on opportunities th.

news source

Business Wire • Oct 8, 2026

news preview

¹ Disclosures

Get started with M1

Invest in STAAR Surgical Company

Open an M1 investment account to buy and sell STAAR Surgical Company commission-free¹. Build wealth for the long term using automated trading and transfers.

Invest in STAA on M1